A Map of Materials Under Development
Plukenesia develops active ingredients and commodities through an integrated approach: correct material identity, quality standardization, biological activity, processing technology, formulation, safety and benefit evidence, and downstream readiness.
Core Commodity: Sacha Inchi
Sacha inchi (Plukenetia volubilis L.) is the ecosystem’s principal commodity. Development covers seeds, native and refined oils, protein fractions, press cake, shells, and by-products. Applications include raw materials, health supplements, functional foods, cosmetics, veterinary products, animal feed, and circular utilization.
Priority Active Ingredients
Curcumin from turmeric is developed as an antioxidant and a potential health and cosmetic ingredient. Lipid-based delivery and dispersion-enhancement technologies address its low solubility and bioavailability.
Brazilin from sappanwood is explored as an antioxidant and functional natural colorant, with emphasis on extract standardization, stability, formulation compatibility, and downstream potential.
Alpha-mangostin from mangosteen peel is studied for antioxidant, skin-care, and wound-healing applications. Nanostructured lipid carriers can improve its dispersion, stability, and delivery.
Catechins from gambir are investigated as antioxidants for pharmaceutical, cosmetic, and food applications, including purification, characterization, stability enhancement, and nanocrystal development.
Piperine from pepper is developed as an active ingredient and bioavailability enhancer, with attention to interactions, dosage, safety, and delivery-system suitability.
The portfolio also includes andrographolide, propolis, marine minerals, proteins, collagen, and other natural-material candidates selected according to need, scientific evidence, source sustainability, and industry opportunity.
Information Framework
Each material profile covers botanical identity or source, plant part and supply chain, marker compounds, biological activity and level of evidence, specifications and standardization, stability or solubility challenges, supporting technologies, research outputs and intellectual property, prototypes and readiness, and opportunities for research, licensing, investment, or co-development.
Development Principles
Claims are presented according to the available level of evidence and do not replace medical advice. Candidates are assessed for safety, quality, benefit, material availability, sustainability, regulation, scale-up capability, and techno-economic feasibility.